Preparation method of injectable thermosensitive chitosan/tempo based-oxidized cellulose hydrogel
11173229 · 2021-11-16
Assignee
- SOONCHUNHYANG UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (Asan-si, KR)
- National Institute Of Forest Science (Seoul, KR)
Inventors
- Byong Taek Lee (Cheonan-si, KR)
- Sun-Young Lee (Seoul, KR)
- Trang Nguyen Ho Minh (Cheonan-si, KR)
- Celine Abueva (Cheonan-si, KR)
- Sang-Jin Chun (Namyangju-si, KR)
- Jae-Gyoung Gwon (Seoul, KR)
Cpc classification
A61L2300/412
HUMAN NECESSITIES
C08L5/08
CHEMISTRY; METALLURGY
A61L2400/12
HUMAN NECESSITIES
A61L27/58
HUMAN NECESSITIES
C08L5/08
CHEMISTRY; METALLURGY
A61L2430/02
HUMAN NECESSITIES
A61L27/50
HUMAN NECESSITIES
A61L27/54
HUMAN NECESSITIES
International classification
A61L27/54
HUMAN NECESSITIES
A61L27/50
HUMAN NECESSITIES
Abstract
The present invention provides a method for preparing an injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel. The injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel exhibits superior biocompatibility through addition of TEMPO-oxidized cellulose nanofibers, and excellent cell proliferation and bone regeneration through cellular interaction, and is gelled in vivo, thus being highly useful as a filler for wound healing and bone regeneration. In addition, the injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel exhibits excellent porosity, has an interconnected structure and is thermogelling, based on thermosensitivity of undergoing a sol-gel transition depending on temperature, thus inducing rapid gelation in vivo and facilitating bone regeneration upon implantation in vivo.
Claims
1. A method for preparing an injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel comprising: diluting a homogeneous suspension of 2,2,6,6-tetramethyl-piperidin-1-oxyl (TEMPO)-oxidized cellulose nanofibers (TOCNFs) in distilled water and adding an aqueous hydrochloric acid solution to the diluted suspension to prepare a TOCNF solution containing TEMPO-oxidized cellulose nanofibers (TOCNFs); dissolving chitosan in an aqueous lactic acid solution to prepare a chitosan solution; mixing the TOCNF solution with the chitosan solution to prepare a chitosan/TOCNF mix solution; and adding glycerolphosphate to the chitosan/TOCNF mix solution to prepare the injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel, wherein the TEMPO-oxidized cellulose nanofibers (TOCNF) are present in an amount of 0.4% (w/v) in the chitosan/TEMPO-oxidized cellulose nanofibers hydrogel, wherein the TOCNF solution and the chitosan solution are mixed in a mix ratio (v/v) of 3:1, wherein the chitosan is present in an amount of 2.25% (w/v) in the injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel.
2. The method according to claim 1, wherein the injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel undergoes sol-gel transition depending on temperature.
3. The method according to claim 1, wherein the injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel is gelled in vivo.
4. The method according to claim 1, wherein the injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel has a porous structure.
5. The method according to claim 1, wherein the glycerolphosphate is present in an amount of 15% (w/v) to 25% (w/v) in the injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel.
6. The method according to claim 1, wherein the injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel facilitates bone regeneration.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) The above and other objects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
DETAILED DESCRIPTION OF THE INVENTION
(10) Hereinafter, examples of the present invention will be described with reference to the annexed drawings in detail to such an extent that a person having ordinary knowledge in the art to which the present invention pertains can easily implement the examples. However, the present invention can be realized in various forms and is not limited to the examples described herein.
EXAMPLE 1
Preparation of CS/TOCNF Hydrogel
(11) In the present invention, a chitosan (CS)/2,2,6,6-tetramethyl-piperidin-1-oxyl (TEMPO)-oxidized cellulose nanofibers (TOCNF) hydrogel was prepared through the following process in accordance with the schematic diagram of CS/TOCNF hydrogel synthesis shown in
(12) Specifically, a 1% TOCNF homogeneous suspension was diluted with distilled water, and a 1% (v/v) aqueous hydrochloric acid solution was added to the diluted suspension while conducting ultrasonication for 30 minutes to adjust pH to 2 and thereby TOCNF solutions containing TEMPO-oxidized cellulose nanofibers (TOCNF) at different concentrations (0.2, 0.4, 0.6, 0.8% w/v) is prepared.
(13) Then, chitosan was dissolved in an aqueous 1% (v/v) lactic acid solution to prepare a 3(w/v) chitosan (CS) solution, and then it was mixed with the TOCNF solution at room temperature in a ratio of 3:1 (CS:TOCNF) (v:v) to prepare a chitosan/TOCNF mix solution. Chitosan (CS) is a cationic polymer electrolyte which has a pKa of about 6.5 and is dissolved only under an acidic environment. Chitosan (CS) was homogeneously dissolved in lactic acid as a solvent.
(14) Finally, 60% (w/v) of a chilled glycerolphosphate (GP) solution was added dropwise to the CS/TOCNF solution which was cooled while continuously stirring in an ice bath for about 20 minutes to prepare a chitosan (CS)/TEMPO-oxidized cellulose nanofibers (TOCNF) hydrogel.
(15) The final concentrations of CS and GP contained in the finally prepared injectable thermosensitive chitosan (CS)/TEMPO-oxidized cellulose nanofibers (TOCNF) hydrogel were 2.25% (w/v) and 20% (w/v), respectively. The CS/TOCNF hydrogel was stored in a liquid phase at 4° C. In addition, the prepared CS/TOCNF hydrogel was gelled at 37° C.
EXAMPLE 2
Analysis of Gelation of CS/TOCNF Hydrogel
(16)
(17) Specifically, as shown in
(18) Gelation time of hydrogel was measured at physiologic temperature (37° C.). As shown in
(19) In addition, gelation time was shortened within an allowed limit for suitable injection. Viscosity of hydrogels did not become thick suddenly. The formation of gel was not excessively rapid, so needle clogging did not occur during the process of in vivo testing. However, injecting hydrogel became harder, because the solution became denser as the content of TOCNF increased. The present inventors also observed that the combination of TOCNF with CS made the solution more viscous, while gelling faster. That is, adding TOCNF to the CS hydrogel increased the viscosity of the solution, thus accelerating the gelation process.
EXAMPLE 3
Analysis of Degradation Profiles of CS/TOCNF Hydrogels
(20)
EXAMPLE 4
Evaluation of Morphology of CS/TOCNF Hydrogel
(21)
(22) Referring to
EXAMPLE 5
FTIR and XRD Analysis of CS/TOCNF Hydrogels
(23) In addition, the formation of CS/TOCNF hydrogels was analyzed by FTIR testing.
(24) As FTIR could not reveal differences between CS/TOCNF and CS/GP hydrogels, X-ray diffraction studies were performed to examine difference in crystalline structure between CS and CS/TOCNF hydrogels. CS hydrogel exhibited only one peak at 2θ of about 30° in XRD patterns (
EXAMPLE 6
In Vitro Biocompatibility Experimentation
(25) In the process of producing biomedical materials, evaluation of biocompatibility is necessary to determine whether a foreign material implanted into the body can exist in harmony with tissues without causing deleterious changes. Biocompatibility was assessed in this study both in vitro and in vivo. L929 fibroblast and pre-osteoblast MC3T3-E1 cells, which are two popular cell lines studied widely for wound healing and bone regeneration, were used in the present experiment to assess the biocompatibility of CS/TOCNF hydrogels.
(26)
(27) Cell viability was assessed mainly through MTT assay (living cell rate) and LDH assay (dead cell rate). Results from MTT assay generally showed that MC3T3-E1 or L929 cells grew better with the presence of TOCNF in CS hydrogel at all kinds of extracted dilutions. The rate of dead cells of both types of cells on hydrogels was low (<20%) based on LDH assay.
(28) LDH assay showed that MC3T3-E1 cells exhibited low cytotoxicity at CS/TOCNF 0.4% and CS/TOCNF 0.6%. L929 cells also exhibited low cytotoxicity and excellent cell growth at hydrogels containing 0.2% to 0.6% of TOCNF. L929 cells exhibited low cytotoxicity and excellent cell growth at hydrogels containing 0.2% to 0.6% of TOCNF. Both MTT assay (
(29) Adhesion behaviors of L929 and MC3T3-E1 cells were reviewed at 7 days after cells were seeded onto the surface of hydrogels.
EXAMPLE 7
In Vivo Biocompatibility Test
(30) Then, in vivo bio-compatibility testing was conducted using the produced CS/TOCNF biomaterials. In vivo testing is the last step to examine the exact response of human body to the materials after initial in vitro evaluation for biocompatibility.
(31)
(32) Based on H&E staining, morphologies of hydrogels were different. As shown in
(33)
(34) After the second week, encapsulation of hydrogels was remarkably developed with arrangement of connective tissues. The color of an encapsulated area became lighter. When the central regions of CS/TOCNF 0.4 and CS hydrogel were observed, the numbers of infiltrated cells and created cell matrixes were increased dramatically from the first week to the second week in both hydrogels, especially for CS/TOCNF 0.4 which had infiltrated cells and matrixes higher than the CS hydrogel (
(35) Then, tissue sections were subjected to immunofluorescence staining to check types of activated macrophage cells surrounding the implanted hydrogels. As shown in
(36) Results of subcutaneous injection in vivo showed that hydrogels caused an inflammatory response in the body, based on the presence of macrophages. This is normal in the initial stage after subcutaneous injection because the body will react to foreign materials injected into the body. The presence of macrophages indicates both inflammatory immune response and the ability of tissue remodeling. After 2 weeks, the quantity of macrophages was decreased and the quantity of alternatively activated macrophages was increased without any symptoms such as pus or allergy, which means that rats have good health conditions. This indicates that CS/TOCNF 0.4 hydrogel has in vivo acceptable tissue compatibility.
(37) The present invention relates to a method for preparing an injectable thermosensitive chitosan/TEMPO-oxidized cellulose nanofibers hydrogel. TOCNF facilitates the sol/gel transition, forms a looser and more porous hydrogel surface, and is more suitable for cell infiltration in vivo. CS/TOCNF hydrogels exhibits better growth and adhesion of L929 fibroblast and pre-osteoblast MC3T3-E1 cells than CS hydrogel. Especially, a CS/TOCNF hydrogel containing a 0.4% (w/v) TOCNF solution exhibits the best cell adhesion and growth. Although hydrogels causes inflammatory response after injected into Sprague Dawley rats, the presence of alternatively activated macrophages increased after 2 weeks demonstrate that CS/TOCNF 0.4 is suitable for regenerating tissues.
(38) Although the preferred embodiments of the present invention have been disclosed for illustrative purposes, those skilled in the art will appreciate that various modifications, additions and substitutions are possible, without departing from the scope and spirit of the invention as disclosed in the accompanying claims.